Ocular and cutaneous sporotrichosis

Aluisio Rosa Gameiro Filho, Carolina Tagliari Estacia, Rodrigo Rosa Gameiro, Leandro de Mattos Fonseca Vieira, Daniella Socci da Costa

1. Introduction

Sporotrichosis is the most common subcutaneous mycosis in the world, especially in regions of tropical or subtropical climate. It is characterized by nodular cutaneous or subcutaneous lesions, with adjacent prominent lymphatic vessels. It is caused by the dimorphic fungus Sporothrix schenckii, usually found in soil and other vegetable matters, and penetrate the organism by either traumatic implantation into the skin or, rarely, by inhalation. In Brazil, the disease is transmitted mostly through bites or scratches of felines contaminated with the fungus. Handling the lesion (e.g., scratching) may lead to secondary contamination and delayed diagnosis. S. brasiliensis is the main etiological agent of the highest feline zoonotic transmission reported in southeastern Brazil since the late 1990s.

Ocular involvement is rare and most reports describe the involvement of the conjunctival and periorbital tissues (presented in only 2.3% of all sporotrichosis cases), which is usually associated with direct facial trauma. Intraocular presentation is rare and a common consequence of hematogenous dissemination from multiple systemic lesions.

We report a case of a 13-year-old girl who sought assistance at the Ophthalmology Department of the Hospital Federal dos Servidores do Estado do Rio de Janeiro, complaining about facial skin nodules that had appeared one month earlier.

1.1. Case report

A 13 years old black healthy female patient, residing in the metropolitan area of Rio de Janeiro, RJ, Brazil complained about nodules in the left malar region that had appeared one month earlier, followed by a similar lesion in left malar region, measuring 2.5 x 2 cm, with a granulomatous grayish lesion that drained a brownish exudate. The right eye and the fundus examination of both eyes were normal. The best-corrected visual acuity (BCVA) was 20/20 in both eyes.

The slit-lamp examination showed, in the left eye, follicles in the lower tarsal conjunctiva, conjunctival hyperemia, lower eyelid swelling, and a granulomatous grayish lesion that drained a brownish exudate. The right eye and the fundus examination of both eyes were normal. The best-corrected visual acuity (BCVA) was 20/20 in both eyes.

The clinical examination showed the presence of a nodular lesion in the inner corner of the left eye measuring 1 x 1 cm (cm), and a lesion in the lower eyelid measuring 3.5 x 2 cm, with a granulomatous appearance and dissemination to the lymphatic chain. There was also a similar lesion in left malar region, measuring 2.5 x 2 cm. The patient also presented painless ipsilateral lymphadenopathy in both preauricular and anterior cervical chains (Fig. 1A–C and 2A-D). Lacrimal apparatus was not involved.
The patient presented low socioeconomic status and reported upon inquiry to have adopted a cat from the streets before the symptoms started. She mentioned the cat was ill and had died a few weeks before the medical appointment reported in this study. She did not remember of any injuries or scratches of the cat in her face.

Considering the epidemiological history and the clinical appearance of the lesions, the diagnosis of sporotrichosis was suspected. A skin biopsy was performed and the specimens were sent for histological analysis. The culture was positive for *Sporothrix brasiliensis*, appearing on SGA (Sabouraud glucose agar) at 25 °C as a delicate branching, molded with pyriform conidia, in a typical flower-like arrangement. The diagnosis of ocular and cutaneous sporotrichosis was established and 200 mg/day of Itraconazole was prescribed for 3 months. The patient presented a gradual and satisfactory improvement until complete

---

**Fig. 1.** A: The patient presented a nodular lesion in the inner corner of the left eye, measuring 1 × 1 cm; a lower eyelid granulomatous lesion, measuring 3.5 × 2 cm, and a similar lesion in the left malar region, measuring 2.5 × 2 cm. B: Cervical lymphadenopathy. C: Facial and ocular granulomatous lesions. The cutaneous and eyelid lesions show complete resolution 3 months after Itraconazole treatment (D, E). Patient remained with a residual scar in her malar region (F).

**Fig. 2.** A: Granulomatous lesion in the lower eyelid of the left eye. B: Involvement of inferior tarsal conjunctiva of the left eye, showing follicles. C: Inner corner nodular lesion. D: Granulomatous malar lesion. The cutaneous and eyelid lesions show complete resolution 3 months after Itraconazole treatment (E, F, G). Patient remained with a residual scar in her malar region (H).
resolution, and only a small scar remained in the left malar region and in the lower eyelid margin of the left eye after the treatment (Fig. 1D–F and 2E–H).

2. Discussion

Ocular sporotrichosis is usually presented as a granulomatous conjunctivitis, in which nodular yellowish elevations involving bulbar or tarsal conjunctiva are present and are often rather difficult to distinguish from follicles. These nodules are grouped and feature a smooth surface, and may be confused with hordeolum and chalazion, delaying the diagnosis in some cases. They may be associated with conjunctival hyperemia and mucopurulent exudate. Parainfa’s oculo-glandular syndrome occurs when granulomatous conjunctivitis is associated with ipsilateral lymphadenopathy, usually involving preauricular, submandibular, and anterior cervical chains.

Other possible presentations are bulbar conjunctivitis with mucosal infiltration, which may be confused with adenoviral conjunctivitis and even MALT lymphoma; epiplebitis; acute or chronic and persistent dacyrocystitis; fungal keratitis, corneal ulceration; and ectropion.

The intraocular involvement may be presented as granulomatous uveitis; iridociclitis; choroiditis, which can be multifocal; retinal granulomas, and endophthalmitis, which may lead to amaurosis. This type of involvement is usually associated with immunosuppressive conditions such as HIV.

We believe that our patient had self-inoculated the fungus when scratching or handling the lesion, which destabilized it and may explain the appearance of multiple lesions. Our patient also used topical steroids as previous treatment, which might have facilitated fungus replication, modifying the morphology of the lesion and making it more exuberant.

For diagnosis, clinical suspicion is the key and culture is the gold standard. Among other tests available, histopathology is nonspecific and may mimic other granulomatous conditions. Intradermal or molecular testing, such as PCR, may also be performed, but they usually present variations of sensitivity and specificity and are not available in most hospitals.

The treatment is similar to the cutaneous form of the disease and it should start as soon as possible to prevent sequelae such as symblepharon and scars. The gold standard is the use of Itraconazole, which should be administered orally in a dose of 200–400 mg/day for 3–6 months (or for 2–4 weeks in addition to the resolution of lesions). Patients using steroids or with immunosuppressive status might benefit from a prolonged treatment time. The most important disadvantage of this drug is the high cost, especially in developing countries, where sporotrichosis is more prevalent.

Fluconazole is another potential azole to be used. Our patient had a complete improvement of her lesions with 3 months of Itraconazole, remaining only a small scar in the left malar region and in the lower eyelid margin of her left eye.

3. Conclusions

Ocular sporotrichosis may be similar to other eye conditions, which can be confusing and challenging to the ophthalmologist, usually delaying diagnosis. It may also postpone treatment and lead to sequelae, as it occurred in the present case. Hence, both the physician and the ophthalmologist should be aware of this condition in order to start the correct treatment as soon as possible.

Funding

No funding was received for this work.

Intellectual property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

Patient consent

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from patient’s legal guardian.

Authorship

All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

We confirm that the manuscript has been read and approved by all named authors.

We confirm that the order of authors listed in the manuscript has been approved by all named authors.

Declaration of competing interest

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Acknowledgments

None.

References

1. Orofino-Costa R, Macedo PM, Bernardez-Engemann AR. Hyperendemia of sporotrichosis in the Brazilian southeast: learning from clinics and therapeutics. Curr Fungal Infect Rep. 2015;9(4):220-228.
2. Almeida-Paes R, Oliveira MME, Freitas DFS, et al. Sporotrichosis in Rio de Janeiro, Brazil: Sporothrix brasiliensis is associated with atypical clinical presentations. PLoS Neglected Trop Dis. 2014;8(9), e3094.
3. Vieira Dias D, Sera CM, Tanue MAG, Hamdan JS. Ocular and concomitant cutaneous sporotrichosis. Mycoses. 1997;40:197–201.
4. Bonifaz A, Tirado-Sánchez. Cutaneous disseminated and extracutaneous sporotrichosis: current status of a complex disease. J Fung. 2017;5(6):1-13.
5. Terra FPD, Rodrigues AM, Fernandes GF, Nishikaku AS, Burger E, Camargo ZP. Exploring virulence and immunogenicity in the emerging pathogen Sporothrix brasiliensis. Negl Trop Dis. 2017;11(8):1–23.
6. Mahajan VK. Sporotrichosis: an overview and therapeutic options. Dermatology Research and Practice. 2014;1:13.
7. Schubach A, Barros MBL, Schubach TM, et al. Primary conjunctival Sporotrichosis: two cases from a zoonotic epidemic in Rio de Janeiro. Cornea. 2005;24(4):491-493.
8. Kashima T, Homma R, Kishi S, Hirato J. Bulbar conjunctival sporotrichosis presenting as a salmon-pink tumor. Cornea. 2010;29(5):573-576.
9. Biancardi AL, Freitas DFS, Valviesse VRGDA, Andrade HB, et al. Multifocal choroiditis in disseminated Sporotrichosis in patients with HIV/AIDS. Retin Cases Brief Rep. 2016;11(1):67-70.
10. Curi ALL, Felix S, Azevedo KML, et al. Retinal granuloma caused by Sporothrix schenckii. Am J Ophthalmol. 2003;136(1):205-207.
11. Macedo PMD, Sztabi´bok ECN, Camargo ZP, et al. Dacryocystitis due to Sporothrix brasiliensis: a case report of a successful clinical and serological outcome with low-dose potassium iodide treatment and oculoplastic surgery. Br J Dermatol. 2015;172(4):116–119.
12. Soto MCR. Sporotrichosis among children of a hyperendemic area in Peru: an 8-year retrospective study. Int J Dermatol. 2017;56(6):868-872.
13. Sharma NL, Mehta KS, Mahajan VK, Kanga AK, Sharma VC, Tegta GR. Cutaneous sporotrichosis of face: polymorphism and reactivation after intralesional triamcinolone. Indian J Dermatol, Venereol Leprol. 2007;73(3):188–190.

14. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America. IDSA Guidelines for Manag. Sporotrichosis. 2007;45:1255–1265.

15. Rodrigues AM, Fernandes GF, Araujo LM, et al. Proteomics-based characterization of the humoral immune response in sporotrichosis toward discovery of potential diagnostic and vaccine antigens. PLoS Neglected Trop Dis. 2015;9(8), e0004016.